<DOC>
	<DOC>NCT00424229</DOC>
	<brief_summary>We are evaluating the incidence of significant hematological response, according to IWG criteria including CR, PR or, major HI, (HI-E, Hl-N,or Hl- P), and cytogenetic response of patients diagnosed with intermediate-2 or high-risk (International Prognostic Scoring System [IPSS]) MDS with a deletion (del) 5q[31]</brief_summary>
	<brief_title>Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]</brief_title>
	<detailed_description>Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for assessment of disease progression) evaluations Subjects may participate in the study for up to 52 weeks ( in patients still responding after 52 weeks, the drug wil continue to be supplied).</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age &gt; 18 years at the time of signing the informed consent form MDS with IPSS scores Int2 or high with deletion 5q(31) Prior thalidomide allowed Documented diagnosis of MDS (RA, RARS, RAEB, RAEBT and CMML with WBC &lt; 13,000/mm3 according to FAB classification) that meets IPSS criteria for intermediate2 or highrisk disease and has an associated del 5q[31] (the deleted chromosomal region must include 5q[31]), with or without additional cytogenetic abnormalities Pregnant or lactating females Prior therapy with lenalidomide MDS with IPSS scores low or Int1 Clinical neuropathy of greater than grade 2 Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML) Recombinant human erythropoietin (rHuEPO) therapy received within 28 days Use of androgens other than for treating hypogonadism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>MDS INT-2MDS HIGH RISKDELETION 5q[31]Lenalidomide</keyword>
</DOC>